

Update on implementation of Pharmacovigilance legislation

EU28: Science Medicines Health, a regulatory system fit for the future

06-07 May 2013, Dubrovnik, Croatia

Franck Diafouka, Pharmacovigilance and Risk Management Sector, Patient Health Protection Unit European Medicines Agency



Content

- 1. Making of the law and its objectives
- 2. Hierarchy of rules
- 3. Prioritised implementation for 2013
- 4. Project governance structure



| | | | | . 🔍 . | | | | | - | | |
|--------|---------------|------|------|-------|------|------|------|------|------|------|------|
| _ | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 |
| | | | | | | | | | | | |
| | l l | | I | I I | l i | i i | | I I | i i | i i | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | I | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | i i | | I | I I | | i i | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | 1 | I I | I | I I | I | | I I | I I | I I | I I | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | i i | | I | I I | | i i | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | i i | i i | l l | i i | | i i | i i | i i | i i | i i | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | i | | | i i | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | i i | | | | | | | |
| 2003 | EC decision | to | I I | I I | I I | I I | I I | I I | I I | I I | |
| | - take an | | | | | | | | | | |
| | sment of the | | | | | | | | | | |
| Comn | nunity syster | n | I I | I İ | I I | ı i | I I | I İ | I İ | I I | |
| of pha | armacovigilar | nce | | | | | | | | | |
| | | | | I | | | | | | | |
| | | - | | | | | | | | | |



| _ | 2003 | 2004 | 2005 | 2006 | | | | | | | |
|-------|--------------------------------|-------|---------------|------|------|------|------|------|------|------|------|
| | | | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 |
| | 1 | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | i | | | | i | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | i | | | | i | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | i | i | | | i | i | i | | | | |
| | | | | | | | | | | | |
| | | 20 | 05: Independ | ent | | | | | | | |
| 200 | 3: EC decision | to ma | idy completed | to | | i | | | | | |
| unde | ertake an | and | d weaknesses | | | | | | | | |
| | ssment of the munity systen | | e EU system | | | | | | | | |
| of ph | narmacovigilar | nce | | | | | | | | | |
| | | | | | | | | | | I I | |



| | | | | – | | | | | | | |
|------|--------------------------|-------|-------------------------------|---------------|------------------------------|--------------|-----------|------|------|-----------|------|
| _ | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 |
| | 1 | | i i | | | | | | | | |
| | | | i I I I | | | | | | | | |
| | | | / I | | | | | | | | |
| | | | | | | | | | | | |
| | | | / I I I | | | | | | | | |
| | | | i I | | | | | | | | |
| | | | i i | | | | | | | | |
| | | | , I I I | | | | | | | | |
| | | | 1 I | | | | | | | | |
| | | | | | | | | | | | |
| | | | , <u> </u> | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | I | , • • | 2006 2008 | : Research, co | ncultation | | | | | |
| | 1 | | | policy develo | | Insultation, | | | | | |
| | | | i i | | | | | | | | |
| | | | | | : Commission | | | | | | |
| | 1 | | 05: Independe | ent l and r | egy to strengt ationalise | nen | | | | | |
| 200 | 03: EC decision | | ap the strength | | macovigilance | | | | | | |
| | ertake an essment of the | | d weaknesses o e EU system | of | | | | | | | |
| Con | nmunity system | י ר | | | | | | | | | |
| of p | harmacovigilan | | | | | | | | | | |
| | | | · · | | | · · · | · · · · · | | | · · · · · | |

| | | | | | | | | | - | | | |
|---------------------|----------------------------|--|---------------------------------|---------------|-------------------------------|-------------------------------------|-----------------|------|------|------|------|--|
| | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | December 2008 - 22 September 2010: Co-decision procedure until | | | | | | | | | | |
| | | | | | | final favour | able vote in th | | | | | |
| | i | | | | Decembe | Parliament er 2008: 'Phar | rma package' | | , | | | |
| | | | | | | ovigilance, Inf and falsified me | | | | | | |
| | | | | | adopted b | by the Europea ion and transm | n | | | | | |
| | | | | | Council a | nd European P co-decision pro | arliament to | | | | | |
| | | | | | pharmaco | | | | | | | |
| | 1 | | | | : Research, co | onsultation, | | | | | | |
| | 1 | | | policy develo | opment | | | | | | | |
| | | | | | 7: Commissior | | | | | | | |
| | 1 | | 05: Independ | ent landr | egy to strengt rationalise | hen | | | | | | |
| 2003: E undertak | C decision | to ma | ap the strength d weaknesses | ns (phari | macovigilance | | | | | | | |
| assessme | ent of the | the | e EU system | | | I | | | | | | |
| | nity system nacovigilan | | | | | | | | | | | |
| | | | | | I | I I | | | I I | | | |

EUROPEAN MEDICINES AGENCY

| | | | | <u> </u> | | | | | - | | | |
|-----|---|---|---|----------------|---|------|----------------------|--|------------------|------|------|--|
| | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | |
| | | | | | | | of Regulati Direc | ber 2010: Pu on (EC) 726/ tive 2001/83 to force in Ju | 2004 and 3/EC | | | |
| | December 2008 - 22 September 2010: Co-decision procedure until final favourable vote in the European Parliament December 2008: 'Pharma package' | | | | | | | | | | | |
| | | (Pharmacovigilance, Information to patients and falsified medicines) adopted by the European Commission and transmitted to Council and European Parliament to start the co-decision procedure for pharmacovigilance | | | | | | | | | | |
| | | | | policy develo | : Research, co opment <u>:</u> Commissior | | | | | | | |
| unc | 03: EC decision dertake an | to ma an | 05: Independend ady completed ap the strength d weaknesses | ent to s | egy to strengt ationalise macovigilance | hen | | | | | | |
| Cor | essment of the mmunity system pharmacovigilar | n | e EU system | | | | | | | | | |

EUROPEAN MEDICINES AGENCY

| | | | | | | | | | . | | |
|------|--|--------------|--|-----------------|--|------|----------------------|--|-------------------|-------------------|--|
| | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 |
| | | | | | | | of Regulati Direc | ber 2010: Pu on (EC) 726/ tive 2001/8: to force in Ju | /2004 and 3/EC | Regulatio Dire | er 2012: Publication of on (EC) 1027/2012 and ective 2012/26/EU force in June and October 2013). |
| | December 2 2010: Co-de final favoura Parliament December 2008: 'Pharn (Pharmacovigilance, Info patients and falsified mea adopted by the European Commission and transmi Council and European Pa start the co-decision proc pharmacovigilance | | | | | | | eptember dure until | | | 2013). |
| | | | | policy develo | : Research, co opment <u>7:</u> Commissior | | | | | | |
| unde | <u>3:</u> EC decision ertake an | to ma and | 05: Independent Didy completed Didy the strength Did weaknesses | ent to ns | egy to strengt ationalise macovigilance | hen | | | | | |
| Com | ssment of the munity systen harmacovigilar | י ר | EU system | | | | | | - | | |

Promote and protect public health by reducing burden of Adverse Drug Reactions and optimising the use of medicines:


- Clear roles and responsibilities
- Science based
- Risk based/proportionate
- Increased proactivity/planning
- Reduced duplication/redundancy
- Integrate benefit and risk

Promote and protect public health by reducing burden of Adverse Drug Reactions and optimising the use of medicines:

- Ensure robust and rapid EU decision-making
- Strengthen the EU Network
- Engage patients and healthcare professionals
- Increase transparency and accountability
- Provide better information on medicines



2. Hierarchy of rules







- Legally binding
- 9 Chapters




- Legally binding
- 9 Chapters




- Legally binding
- 9 Chapters




- Legally binding
- 9 Chapters




- Legally binding
- 9 Chapters




- Legally binding
- 9 Chapters




- Legally binding
- 9 Chapters




- Legally binding
- 9 Chapters



- Legally binding
- 9 Chapters



- Legally binding
- 9 Chapters



2. Hierarchy of rules - Good pharmacoVigilance Practice (GVP)

- Self-standing guidance on pharmacovigilance replacing Volume 9A
- Addressed to EU Marketing Authorisation Holders, Competent Authorities in Member States and Agency
- Developed within EU network
- 8 weeks public consultation
- 2 types of 'Chapters':
 - Modules for major processes
 - Product or populations specific (P)
- GVP structure:
 - A: Introduction
 - B: Structures and processes
 - 21 C: Operation of the EU network

2. Hierarchy of rules - Good pharmacoVigilance Practice (GVP)

Self-standing guidance on Module Module II Module III Pharmacovigilance Pharmacovigilance Pharmacovigilance pharmacovigilance replacing Volume 9A systems and their system master file quality systems Addressed to EU Marketing Module IV Module V Module VI Pharmacovigilance Management and Authorisation Holders, Competent reporting of adverse Authorities in Member States and Module VII Module VIII Agency Module IX Periodic safety **Post-authorisation** Signal management update reports safety studies Developed within EU network Good pharmacoVigilance Module X Practice (GVP) Additional 8 weeks public consultation 2 types of 'Chapters': Module XV Safety Modules for major processes Product or populations specific (P) GVP structure: A: Introduction B: Structures and processes Under development 22 **Published** C: Operation of the EU network Public consultation

Published

2. Hierarchy of rules - Good pharmacoVigilance Practice (GVP)

Self-standing guidance on Module I Module II Module III Pharmacovigilance Pharmacovigilance Pharmacovigilance pharmacovigilance replacing Volume 9A systems and their system master file quality systems Addressed to EU Marketing Module IV Module V Module VI Pharmacovigilance **Risk management** Management and Authorisation Holders, Competent reporting of adverse Authorities in Member States and Module VII Module VIII Agency Module IX Periodic safety **Post-authorisation** Signal management update reports safety studies Developed within EU network Good pharmacoVigilance Module X Practice (GVP) Additional 8 weeks public consultation 2 types of 'Chapters': Module XV Module XVI Safety **Risk minimisation** Modules for major processes measures Product or populations specific (P) GVP structure: PI-Vaccines (opened 12/04/13)

Under development


Public consultation

- A: Introduction
- B: Structures and processes
- 23 C: Operation of the EU network

Hierarchy of rules - Good pharmacoVigilance Practice (GVP)

Good

- Self-standing guidance on pharmacovigilance replacing Volume 9A
- Addressed to EU Marketing Authorisation Holders, Competent Authorities in Member States and Agency
- Developed within EU network
- 8 weeks public consultation
- 2 types of 'Chapters':
 - Modules for major processes
 - Product or populations specific (P)
- GVP structure:
 - A: Introduction
 - B: Structures and processes
 - 24 C: Operation of the EU network





 Prioritised implementation agreed by EMA Management Board in December 2011 and 2012


Criteria for prioritisation:

- Firstly, public health activities
- Secondly, transparency and communication activities
- Thirdly, simplification activities (primarily for pharmaceutical industry)
- Activities grouped into four main topic areas:
 - Collection of key information on medicines
 - Better analysis and understanding of data and information
 - Regulatory action to safeguard public health
 - Communication with stakeholders
- Traffic light:



Not started

On-going implementation



Collection of key information on medicines (1/4)

1. Risk Management Plans:

Establishment and operation of new procedure for requesting and assessing RMP


2. Periodic Safety Update Reports (PSUR):

Operation of new procedures related to PSURs for CAPs*

Development, maintenance and publication of harmonised birthdates to support PSUR submission

Handling of PSURs for active substances contained in both CAPs and NAPs* in accordance with URD* list 2012 2013

- Started July 2012
- Templates for industry (Oct)
- Format compulsory (Jan 2013)



First list published in Oct2012 (monthly update)





Collection of key information on medicines (2/4)

| 3. Post-Authorisation Safety and Efficacy Studies: | 2012 | 2013 | |
|---|------|------|----------------------------------|
| Implementation of the PASS procedure for protocols approval and results management for CAPs | | | - Started July 2012 |
| Public consultation on delegated act on PAES by the Commission | | | - From 28/11/2012 to 18/02/13 |
| PASS: Operate the procedure for initial protocol and protocol amendment endorsement and results management for NAPs | | NEW | |
| PASS: Establish a procedure to encourage MAHs to collaborate on PASS affecting multiple medicinal products | | NEW | |
| PAES: Deliver scientific guidance on methodological aspects (expert workshop) 27 | | NEW | |


3. Prioritised implementation of the pharmacovigilance legislation by the EMA **Collection of key information on medicines** (3/4)

| 4. Electronic submission of core medicine information by MAHs ('Article 57'): | 2012 | 2013 | |
|--|------|------|--|
| Start validation of received information | | | |
| Initiate limited quality assurance of data being submitted on medicinal products authorised in EU | | NEW | |
| Achieve an agreement with pharmaceutical industry on the submission of varied marketing authorisations in view of operating the process for submission of maintenance data at a later stage | | NEW | |



Format for electronic submission of product information –

phased implementation



NOTE: Dedicated helpdesks: art57@ema.europa.eu and eudravigilance@ema.europa.eu





(finalised in October 2012)

ISO 11239:2012, Health Informatics, Identification of Medicinal Products standard

Data elements and structures for unique identification and exchange of regulated information on <u>pharmaceutical dose</u> forms, units of presentation, routes of administration and packaging ISO 11238: 2012, Health Informatics, Identification of Medicinal Products standard Data elements and structures for unique identification and

exchange of regulated information on substances

3. Prioritised implementation of the pharmacovigilance legislation by the EMA **Collection of key information on medicines** (3/4)

| 4. Electronic submission of core medicine information by MAHs ('Article 57'): | 2012 | 2013 | |
|--|------|------|--|
| Start validation of received information | | | |
| Initiate limited quality assurance of data being submitted on medicinal products authorised in EU | | NEW | |
| Achieve an agreement with pharmaceutical industry on the submission of varied marketing authorisations in view of operating the process for submission of maintenance data at a later stage | | NEW | |

Collection of key information on medicines (4/4)

5. Reporting by patients:

Cooperation with Member States to provide information to patients on direct reporting

Prepare guidance on patient reporting in cooperation with the Member States

6. List of medicines withdrawn for safety reasons:

Develop a business process for establishing, maintaining and publishing such list

2012

NEW

2013

- Core data fields agreed by Member States (June 2012)

NEW

Based on 2012 changes to pharmacovigilance legislation

Better analysis/understanding of data and information (1/2)

| 1. EudraVigilance and signal detection | 2012 | 2013 | |
|--|------|-------------|--|
| Operation of revised signal detection process for CAPs | | | - Started July 2012 |
| Support Member States to operate the new EU signal detection processes for NAPs | | | Started July 2012 Signal work-sharing list published (Oct 2012) |
| Start of signal management through the Pharmacovigilance and Risk Assessment Committee (PRAC) | | | - Started Sept 2012 |
| Continuation of maintenance work for the current EV system including data quality | | | - As planned |
| Implementation of web-publishing of adverse reaction data (further to the EV Access Policy) | | | - Delivered in May 2012 |
| Perform analyses of EV data for NAPs (in collaboration with MSs Competent Authorities ₃ through work-sharing) | | NEW | |

Better analysis/understanding of data and information (2/2)

2012

2. Additional monitoring:

Develop and publish the list of medicines with additional monitoring status

Monitor that product information for relevant CAPs is updated to reflect this status

3. IT systems to support processing and analysis of data:

Finalisation of business requirements for enhanced IT systems

4. Medication errors:

Establish guidance/best practice considerations on medication error prevention and reporting

2013

- Initial list published on 25 April 2013

On-going in 2013



Following stakeholder
 workshop held on
 28/02/13-01/03/13

'Black symbol' for products under additional monitoring

- Black symbol:
 - Selected by the European Commission following a recommendation of the PRAC (after involving stakeholders) on 7 March 2013
 - Inverted equilateral black triangle



- New text in Product Information
 - SPC text: <{Black symbol} > This medicinal product is subject to additional monitoring. This is to allow any safety information to be identified rapidly. Healthcare professionals are encouraged to report any suspected adverse reactions. See section 4.8.>
 - PL text: <{Black symbol} This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
- List of products under additional monitoring
 - Prepared by the EMA/PRAC: initial list published on 25th April 2013 and updated every month
- In April 2013, launch of wide public communication campaign coordinated by EMA

Better analysis/understanding of data and information (2/2)

2. Additional monitoring:

Develop and publish the list of medicines with additional monitoring status

Monitor that product information for relevant CAPs is updated to reflect this status

3. IT systems to support processing and analysis of data:

Finalisation of business requirements for enhanced IT systems

4. Medication errors:

Establish guidance/best practice considerations on medication error prevention and reporting

2012 2013

- Initia April 2

- Initial list published on 25 April 2013


On-going in 2013



Following stakeholder workshop held on 28/02/13-01/03/13

Regulatory action to safeguard public health (1/2)

| 1. Scientific committees and decision- making: | 2012 | 2013 | |
|--|------|------|---|
| Establishment and running of new committee (PRAC) and new responsibilities for CMD(h) | | | - Established July 2012 |
| PRAC outputs: establish a strategy for supporting PRAC assessments and recommendations with best evidence, including aspects of effectiveness of risk minimisation/impact of regulatory action | | NEW | |
| 2. Strengthening referral procedures: | | | |
| Operation of new referral procedure (Urgent Union Procedure) | | | First referral launched in Oct 2012 |
| Redesign the 2012 implemented procedure and business process to include 2012 changes | | NEW | |



38

3. Prioritised implementation of the pharmacovigilance legislation by the EMA **Regulatory action to safeguard public health** (2/2)

| 3. Pharmacovigilance Inspections: | 2012 | 2013 |
|---|------|------|
| Develop and implement a revised process for the coordination of pharmacovigilance inspections | | NEW |

Communication with stakeholders (1/2)

| 1. Online publishing of information: | 2012 | 2013 | |
|--|------|--|--|
| Publication (on EMA website) of agendas, minutes, assessments, approvals, recommendations, opinions and decisions of PRAC, CMD(h) and CHMP. | | Started July 2012 for PRAC agendas and minutes | |
| | | NEW | Publish agendas and minutes of CHMP meetings |
| 2. Coordination of safety messages: | | | |
| Operation of the coordination of Member States' safety announcements for non-CAPs. | | | - Started July 2012 |
| 3. Public hearings: | | | |
| Develop concept of public hearings (incl. criteria and methodologies) | | | - Status in April 2013 |
| Introduction of public hearings in the context of Urgent Union Procedure | | | - Status in April 2013 |



Transparency of activities for Pharmacovigilance Risk Assessment Committee

Legal notice: EMA website serves as the EU Medicines Web-portal

- Agenda is published on Day 1 of PRAC by mid-day
- Meeting highlights are published on Friday of PRAC week
- Safety referrals are published on Friday of PRAC week
- Minutes are published on the following month after adoption


Communication with stakeholders (2/2)

| 4. Risk Management Plans summaries: | 2012 | 2013 |
|--|------|-------------|
| Agree modalities to publish summary information for RMPs | | NEW |
| 5. European Medicines web-portal: | | |
| Initiate research and design work | | NEW |



| Topics | Activities |
|--|--|
| Literature monitoring | Outsourcing and population of EudraVigilance with case reports. |
| EudraVigilance | Delivery of enhanced functionalities and IT system audit (Q4 2015 at least due to delayed development work). |
| Article 57(2) data submission and handling | Quality check and publication of controlled structured lists of medicinal products, substances and other key controlled terms. |
| Periodic Safety Update Reports | Delivery of PSUR repository and single PSUR assessment process for NAPs with input from analyses of ADR data. |
| Risk Management System | Define key indicators for measuring the effectiveness of risk minimisation and establish monitoring system |
| Transparency and communication | Delivery of EU Medicines web-portal and public hearings outside Urgent Union Procedure. |

4. Project Governance structure - 2011/2012 Project Governance Structure





4. Project governance structure – revised Project Governance Structure


- Key drivers:
 - Complete development of remaining deliverables as per prioritised implementation agreed with EMA MB in Dec 2011 and 2012
 - Further integrated, streamlined and efficient implementation recognising the need for process efficiency and resource availability across the EU Network
 - Enhanced communication, information sharing and cross working across
 Project Teams as well as Stakeholders liaison management
 - Improved management and resolution of issues and gaps
 - Emphasis on NAPs-related issues
 - Reviewed Project groups membership, considering membership of ICT experts
 - Better integration and best use of available resources



4. Project governance structure – revised Project Governance Structure

- Environmental factors:
 - DG SANCO proposal for Joint Action on Pharmacovigilance to support Member States to find solutions for organising and running their pharmacovigilance system in the context of the new pharmacovigilance legislation in the EU (unlikely to have operational impact before Q4 2013)
 - Resources constraints across the EU Network
 - New changes to Pharmacovigilance legislation
 - On-going changes to variations and fees regulations

4. Project governance structure – revised Project Governance Structure





Thank you!

Any question?